Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study

Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant t...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 10; no. 11; p. e0142425
Main Authors: Stagg, Helen R., Brown, James, Ibraim, Elmira, Riekstiņa, Vija, Viiklepp, Piret, Cīrule, Andra, Cocei, Horia, Danilovitš, Manfred, Dravniece, Gunta, Jackson, Charlotte, White, Peter J.
Format: Journal Article
Language:English
Published: United States Public Library of Science 11.11.2015
Public Library of Science (PLoS)
Subjects:
Antitubercular Agents - therapeutic use
Cross-Sectional Studies
Demographics
Demography
Drug development
Drug resistance
Drug Resistance, Multiple, Bacterial - drug effects
Drug therapy
Epidemiology
Estonia - epidemiology
Female
Fluoroquinolones - pharmacology
Fluoroquinolones - therapeutic use
Hospitals
Humans
Infectious diseases
Innovations
Laboratories
Latvia - epidemiology
Lung diseases
Male
Medical screening
Microbial drug resistance
Multidrug resistance
Multidrug resistant organisms
Patients
Pharmacological research
Precision medicine
Public health
Romania - epidemiology
Tuberculosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Tuberculosis, Multidrug-Resistant - microbiology
Latvia
Romania
Estonia
United Kingdom > UK
ISSN:1932-6203, 1932-6203
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Globally, there is substantial concern regarding the challenges of treating complex drug resistance patterns in multidrug resistant tuberculosis cases. Utilising data from three different settings (Estonia, Latvia, Romania) we sought to contrast drug susceptibility profiles for multidrug resistant tuberculosis cases, highlight the difficulties in designing universal regimen, and inform future regimen selection. Demographic and microbiological surveillance data for multidrug resistant tuberculosis cases from 2004-13 were analysed. High levels of additional resistance to currently recommended second line drugs were seen in all settings, with extensive variability between countries. Accurate drug susceptibility testing and drug susceptibility testing data are vital to inform the development of comprehensive, flexible, multidrug resistant tuberculosis guidance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Conceived and designed the experiments: HRS GD PJW. Analyzed the data: HRS JB CJ GD PJW. Contributed reagents/materials/analysis tools: EI VR PV AC HC MD. Wrote the paper: HRS JB EI VR PV AC HC MD GD CJ PJW. Provision of data: EI VR PV AC HC MD.
These authors also contributed equally to this work.
Competing Interests: The authors of this manuscript have read the journal's policy and have the following competing interests: Dr. Stagg reports personal fees and other from Otsuka Pharmaceutical, grants from National Institute for Health Research, UK, during the conduct of the study; non-financial support from Sanofi, outside the submitted work. Dr. Brown reports grants and personal fees from Otsuka Pharmaceuticals, during the conduct of the study. Dr. White reports grants and personal fees from Otsuka, during the conduct of the study. Dr. Danilovits reports personal fees and other from Otsuka Pharmaceutical, during the conduct of the study. Dr. Viiklepp reports grants from UCL Consultants Ltd, during the conduct of the study. Dr. Ibraim reports personal fees and non-financial support from Otsuka SA, during the conduct of the study; grants from German Centre for Infection Research- DZIF, outside the submitted work. Dr. Dravniece reports grants and personal fees from Otsuka, during the conduct of the study. Dr. Cocei reports grants from Otsuka SA, during the conduct of the study; grants from Romanian National Tuberculosis Programme, grants from Norway Grants, outside the submitted work. Dr. Jackson reports personal fees from Otsuka Pharmaceutical, grants from National Institute for Health Research, during the conduct of the study. Dr. Riekstina reports personal fees from Otsuka Pharmaceutical (Switzerland) during the conduct of the study. Dr. Cirule has nothing to disclose. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0142425